Ureter Cancer

This is a type of cancer that starts in the ureter, which is a tube that carries urine from the kidneys to the bladder. It can block the flow of urine, causing problems like kidney swelling and infections. Blood in the urine is a common sign.

Condition

What people with Ureter Cancer report

Every report comes from a Lived member, sent anonymously.

Have you had Kidney and Ureter Removal for Ureter Cancer?

NameHow it went

About Ureter Cancer

What It Is

Ureter cancer is cancer that starts in the lining of a ureter, one of the two thin tubes that carry urine from each kidney down to the bladder. Almost all of these cancers are urothelial carcinomas (also called transitional cell carcinomas), which grow from the same kind of stretchy lining cells found in the bladder and in the renal pelvis, the funnel inside the kidney where urine collects. Doctors group ureter and renal pelvis cancers together as upper tract urothelial carcinoma. It is a different disease from renal cell carcinoma, the more common kind of kidney cancer, and it is treated differently. The most common sign is blood in the urine, which may turn it pink, red or cola-colored or may show up only on a urine test. A tumor can also partly block the ureter, so urine backs up and the kidney swells, which can cause a dull ache in the back or side that does not go away. Early tumors often cause no symptoms at all. Ureter cancer is rare, accounting for only a small share of urothelial cancers, and it is most often found in people over 70.

Causes & Risk Factors

Ureter cancer develops when changes build up in the DNA of the lining cells, and many of the known risk factors are things that expose that lining to harmful substances carried in urine. Smoking is the most important risk factor that can be changed. People who have had bladder cancer are at higher risk, because the same lining runs through the whole urinary tract. Other contributors include long-term heavy use of certain pain medicines, notably phenacetin; workplace exposure to some dyes and chemicals used in making leather, textiles, plastics and rubber; and aristolochic acid, a toxin in some traditional herbal remedies that is linked to a kidney disease seen in the Balkans. Chronic irritation from long-standing stones and infection is linked to a less common type called squamous cell carcinoma. Some cases are inherited. Lynch syndrome, a genetic condition best known for raising the risk of colon and uterine cancers, also raises the risk of upper tract urothelial cancer. Ureter cancer is about three times more common in men than in women. Having a risk factor does not mean someone will develop this cancer, and many people who do have no obvious risk factor.

How It's Diagnosed

Evaluation usually starts with a urine test and a CT urogram, a contrast CT scan that includes delayed pictures taken after the dye has filtered into the urine, so the inside of the kidneys and ureters stands out. People who cannot have CT contrast may have an MRI version instead. A cystoscopy, in which a thin scope is passed into the bladder, checks for tumors there, since bladder and upper tract cancers often occur together. The key test is ureteroscopy: a thin scope is passed up through the bladder into the ureter, usually under anesthesia, so the urologist can see the tumor, take a biopsy and collect fluid to look for cancer cells (cytology). The findings are used to sort the cancer into low-risk or high-risk groups based mainly on grade (how abnormal the cells look under a microscope), size, whether there is more than one tumor, and whether imaging suggests it has grown into the wall. Low-grade cancers tend to grow slowly and stay on the surface, while high-grade cancers are more likely to invade and spread. Because a biopsy from inside a narrow tube is small, it can underestimate how deep a cancer goes, so the final stage is often confirmed only after surgery. Stage describes how far the cancer has grown, from stage 0 (only in the inner lining) through stages I to III (into the connective tissue, the muscle layer, then the surrounding fat) to stage IV (into nearby organs, lymph nodes or distant sites such as the lungs, liver or bone). Chest imaging may be added to look for spread. Guidelines also recommend testing the tumor tissue for signs of Lynch syndrome, and offering genetic counseling and blood testing when results or family history point that way, because a diagnosis of Lynch syndrome changes cancer screening for the person and their relatives.

Treatment Options

Treatment depends mostly on the risk group, the tumor's location along the ureter and how well both kidneys work. For low-risk tumors, the usual first choice is kidney-sparing treatment: the tumor is destroyed with a laser or similar tool passed through a ureteroscope, leaving the kidney and ureter in place. The trade-off is commitment to repeated scopes, the first within about three months, because these tumors often come back, and the ureter can scar and narrow (a stricture) after treatment. If a low-risk tumor grows, multiplies or turns out to be higher grade, surgery is recommended. For high-risk tumors, the standard operation is a radical nephroureterectomy, which removes the kidney, the whole ureter and a small cuff of bladder where the ureter enters it. The entire ureter is taken because cancer can recur anywhere along it. When a tumor is limited to the lower part of the ureter, a surgeon may instead remove only that section and reattach the healthy ureter to the bladder, which keeps the kidney. Nearby lymph nodes are usually removed during surgery for high-risk disease to stage it accurately. A single dose of chemotherapy placed in the bladder around the time of surgery is recommended for eligible people because it lowers the chance of a later bladder tumor; in one large trial, first-year bladder recurrence fell from about 27% to 17%. Losing a kidney matters for more than kidney health. Cisplatin, the most effective chemotherapy drug for this cancer, depends on good kidney function, so for high-risk cancer doctors may recommend cisplatin-based chemotherapy before surgery, while both kidneys still work. After surgery, chemotherapy is offered when the cancer turns out to have grown into the muscle wall or beyond or reached lymph nodes, if it was not given beforehand. Nivolumab (Opdivo), an immunotherapy drug that helps the immune system attack cancer, is approved after surgery for urothelial cancer at high risk of returning; it can cause immune-related inflammation in organs such as the bowel, lungs, liver or glands, which needs monitoring. When the cancer has spread to distant sites, surgery is generally not the first treatment. Systemic treatment with chemotherapy and immunotherapy, as used for advanced bladder cancer, aims to shrink the cancer, control symptoms and extend life, and clinical trials are often an option. For people who are very frail or would likely need dialysis after any operation, careful monitoring alone or treatment aimed only at symptoms such as bleeding can be a reasonable choice.

What to Expect

Outlook depends most on how deep the cancer has grown and its grade. Cancers found while still confined to the lining are cured in most people, while cancers that have grown through the ureter wall or spread are much harder to cure. Many cases are found at a later stage, which is one reason blood in the urine deserves prompt attention. Follow-up is long and is part of treatment, not an afterthought. Because the whole urinary lining is vulnerable, new tumors often appear in the bladder after upper tract cancer: after nephroureterectomy for a ureter tumor, roughly one in four people develops one. Most people therefore have regular cystoscopies, starting every few months and spacing out to once a year, along with CT scans of the urinary tract and sometimes the chest. People who kept their kidney through scope treatment also need repeated ureteroscopies. Many find the schedule of procedures and scans to be one of the more demanding parts of living with this cancer. After a kidney is removed, the remaining kidney takes over, and many people do well. For those who already had reduced kidney function, diabetes or high blood pressure, kidney function needs ongoing checks, and some are referred to a kidney specialist. Stopping smoking lowers the risk of new urothelial tumors and helps recovery, and staying active and eating well support long-term health. If Lynch syndrome is found, family members may benefit from genetic testing and earlier screening for related cancers.

When to Seek Help

See a clinician if you notice blood in your urine, even once and even if it goes away or causes no pain, or if a test finds blood you cannot see. A pain in the back or side that does not go away also deserves evaluation. If you have been treated for ureter or bladder cancer, report new blood in the urine before your next scheduled check rather than waiting. After a ureteroscopy, or while a ureteral stent (a small tube that keeps the ureter open) is in place, call the care team promptly for chills, a fever of 101°F (38.3°C) or higher, cloudy or foul-smelling urine, or new pain in the side or kidney area, since these can signal infection in a blocked or recently treated kidney. Follow your team's discharge instructions about when symptoms need urgent care.

Questions to Ask Your Doctor

  1. 1.Is my tumor low-risk or high-risk, and what findings put it in that group?
  2. 2.Is kidney-sparing treatment a reasonable option for me, and what would the follow-up scopes involve?
  3. 3.How is losing a kidney likely to affect my kidney function, and should I have chemotherapy before surgery because of that?
  4. 4.Should my tumor be tested for Lynch syndrome, and what would a positive result mean for my family?
  5. 5.What will my surveillance schedule look like over the next few years, and which symptoms should prompt a call between visits?

Last reviewed • Oct 2026

Educational content, not medical advice.